Core Viewpoint - WuXi Biologics reported a revenue increase of 9.6% year-on-year for 2024, but net profit declined slightly, with a notable drop in revenue from the China region by 9.6% [3][5]. Financial Performance - Total revenue for 2024 reached RMB 18.675 billion, up from RMB 17.034 billion in 2023, marking a 9.6% increase [4]. - Gross profit was RMB 7.651 billion, reflecting a 12.1% increase, with a gross margin of 41.0% [4]. - Net profit was RMB 3.945 billion, a 10.5% increase, while profit attributable to shareholders decreased by 1.3% to RMB 3.356 billion [4][5]. - Adjusted net profit attributable to shareholders was RMB 4.784 billion, up 1.8% [4]. Revenue Breakdown - Revenue from North America was RMB 10.696 billion, accounting for 57.3% of total revenue, with a year-on-year growth of 32.5% [6]. - European revenue was RMB 4.323 billion, down 15.9%, while revenue from China was RMB 2.820 billion, down 9.6% [6][7]. - The decline in China revenue was attributed to a challenging financing environment and the transfer of projects to overseas companies [6][7]. Business Segments - Revenue from biopharmaceuticals was RMB 14.731 billion, representing 78.9% of total revenue, while XDC revenue doubled to RMB 3.944 billion [9]. - Pre-IND service revenue grew by 30.7% to RMB 7.062 billion, while late-stage clinical services and commercial production revenue decreased by 3.2% to RMB 7.485 billion [9]. Future Outlook - The company projects a revenue growth of 12% to 15% for 2025, with core business revenue expected to grow by 17% to 20% [9]. - The CEO emphasized the company's resilience and strategic focus in a complex macro environment, indicating a strong growth momentum for the future [9].
药明生物去年营收增近一成：净利下滑，中国区收入降9.6%